Beigene Ltd
HKEX:6160
Intrinsic Value
Beigene Ltd is a biotechnology company in the commercial stage. [ Read More ]
The intrinsic value of one Beigene Ltd stock under the Base Case scenario is 126.33 HKD. Compared to the current market price of 89.85 HKD, Beigene Ltd is Undervalued by 29%.
Valuation Backtest
Beigene Ltd
Run backtest to discover the historical profit from buying and selling Beigene Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Beigene Ltd
Current Assets | 29.6B |
Cash & Short-Term Investments | 22.3B |
Receivables | 2.5B |
Other Current Assets | 4.7B |
Non-Current Assets | 10.6B |
Long-Term Investments | 643.3m |
PP&E | 8.5B |
Intangibles | 967.8m |
Other Non-Current Assets | 515.4m |
Current Liabilities | 9.5B |
Accounts Payable | 3.3B |
Accrued Liabilities | 1.2B |
Short-Term Debt | 2.2B |
Other Current Liabilities | 2.7B |
Non-Current Liabilities | 3.4B |
Long-Term Debt | 1.7B |
Other Non-Current Liabilities | 1.7B |
Earnings Waterfall
Beigene Ltd
Revenue
|
15.6B
CNY
|
Cost of Revenue
|
-2.4B
CNY
|
Gross Profit
|
13.1B
CNY
|
Operating Expenses
|
-22.3B
CNY
|
Operating Income
|
-9.2B
CNY
|
Other Expenses
|
2.1B
CNY
|
Net Income
|
-7.1B
CNY
|
Free Cash Flow Analysis
Beigene Ltd
Profitability Score
Profitability Due Diligence
Beigene Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Beigene Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Beigene Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Beigene Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Beigene Ltd
According to Wall Street analysts, the average 1-year price target for Beigene Ltd is 138.17 HKD with a low forecast of 122.06 HKD and a high forecast of 163.12 HKD.
Shareholder Return
Price
Beigene Ltd
Average Annual Return | 20.06% |
Standard Deviation of Annual Returns | 30.52% |
Max Drawdown | -73% |
Market Capitalization | 123.6B HKD |
Shares Outstanding | 1 362 652 101 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217, BGB-A445, BGB-11417, BGB-10188 and BGB-15025. The Company's business covers China, the United States, Australia, Canada, Singapore, Russia, Brazil, Europe and other countries and regions.
Contact
IPO
Employees
Officers
The intrinsic value of one Beigene Ltd stock under the Base Case scenario is 126.33 HKD.
Compared to the current market price of 89.85 HKD, Beigene Ltd is Undervalued by 29%.